Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus rhamnosus

What does the research say about Lactobacillus rhamnosus?

12 health outcomes synthesised

Lactobacillus rhamnosus has been investigated across 12 health outcomes, with the most researched area being reduced inflammation (13 studies). However, the overall evidence is rated low or very low due to small study sizes, publication bias, and a predominance of non-human models. Effective doses and specific populations remain poorly defined across the literature.

Strongest evidence: None of the outcomes reached high or moderate evidence strength; all are rated low or very low. The most extensively studied outcome is reduced inflammation, with 13 studies all reporting benefit, but only 2 reached statistical significance. The evidence is predominantly from in vitro and animal models, with limited human data.

Mixed or weaker evidence: All other outcomes (11) have low or very low evidence with 3–5 studies each. For example, improved immune function (4 studies), skin barrier function (4 studies), and glycemia (3 animal studies) all show beneficial directions but are limited by small sample sizes and lack of statistical significance. Several outcomes — intestinal barrier function, gut health — rely on studies that did not directly test L. rhamnosus, reducing applicability.

Effective dose patterns: No consistent effective dose emerged. None of the 12 syntheses reported an effective dose; doses, forms, and durations were either not reported or varied too much to synthesize.

Population insights: Human populations studied include children and adolescents with asthma, adults with non-dialysis chronic kidney disease, individuals with autism spectrum disorder, and oncological patients. However, most evidence comes from animal models (rodents, poultry, aquaculture) or in vitro experiments, making direct human translation uncertain.

Notable caveats: Across all syntheses, common caveats include: publication bias (null results less likely to be published), small study numbers (3–13), low statistical significance (most studies not significant), and a reliance on non-human models. Additionally, some syntheses included studies that did not use L. rhamnosus directly, further weakening conclusions.

Frequently asked

  • What is Lactobacillus rhamnosus good for according to research?
    Research has explored Lactobacillus rhamnosus for 12 health outcomes, with the most studied being reduced inflammation (13 studies). Other areas include improved skin barrier function, immune function, glycemia, and gut health. However, all evidence is rated low or very low, and most findings come from animal or lab studies rather than human trials.
  • What dose of Lactobacillus rhamnosus is typically used in studies?
    No consistent effective dose was reported across any of the 12 research syntheses. Doses, forms (e.g., live bacteria vs. lysate), and study durations were either not mentioned or varied too widely to identify a typical regimen.
  • Who benefits most from Lactobacillus rhamnosus?
    Human populations where benefits have been reported include children and adolescents with asthma, people with non-dialysis chronic kidney disease, individuals with autism spectrum disorder, and some oncological patients. However, most evidence is from animal models, so these findings are preliminary and may not translate directly to humans.
  • Are there caveats or limitations in the research on Lactobacillus rhamnosus?
    Yes, several important caveats apply across all studies: publication bias (positive results are more likely to be published), small study sizes (3–13 studies per outcome), low statistical significance (most individual studies did not reach significance), and heavy reliance on non-human models. Some syntheses also included studies that tested other probiotic strains, reducing confidence in effects specific to L. rhamnosus.
  • Does Lactobacillus rhamnosus help reduce inflammation?
    Thirteen studies reported beneficial effects on reducing inflammation, with effect sizes predominantly moderate. However, the evidence strength is low because only 2 of the 13 studies reached statistical significance, and most data come from in vitro or animal models. Human trial evidence is limited and exploratory.
  • Does Lactobacillus rhamnosus improve gut health?
    Three studies (all reviews or non-clinical) reported beneficial effects on gut health, with moderate effect sizes. However, none of the studies reported statistically significant results, and the evidence is rated very low. Applicability to humans is limited because the studies focused on animal and aquaculture populations.

Most-studied combinations with Lactobacillus rhamnosus

most supplement research is combination research
Also studied with:Lactobacillus gasseri (3), Lactobacillus acidophilus (2), Bifidobacterium plantarum (3), Lactobacillus plantarum (2), bifidobacterium longum (2)
Back to top